AstraZeneca's Baxdrostat meets main goal in high blood pressure study

Oct 7 (Reuters) – AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension. (Reporting by Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)